University of the Witwatersrand and Oxford University research shows vaccine has reduced efficacy against mutation
British drugmaker AstraZeneca said on Saturday that its vaccine developed with the University of Oxford appeared to offer only limited protection against mild disease caused by the South African variant of Covid-19, based on early data from a trial.
The study from South Africa’s University of the Witwatersrand and Oxford University showed the vaccine had significantly reduced efficacy against the South African variant, according to a Financial Times report published earlier in the day.
